Last reviewed · How we verify

Hydatidiform mole, benign — Treatment Landscape & Competitive Intelligence

Hydatidiform mole, benign (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hydatidiform mole, benign, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Prepidil DINOPROSTONE Pfizer Prostaglandin Analog [EPC] Prostaglandin E2 receptor EP4 subtype 1977-01-01
Enzaprost DINOPROST Pfizer dinoprost Prostaglandin F2-alpha receptor 1976-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 2 drugs in Hydatidiform mole, benign

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hydatidiform mole, benign:

Cite this brief

Drug Landscape (2026). Hydatidiform mole, benign — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hydatidiform-mole-benign. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing